When should the BioFire (FilmArray multiplex PCR) system be used in the blood culture workflow?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

When to Use BioFire in the Blood Culture Workflow

BioFire (FilmArray BCID2) should be performed immediately upon blood culture bottle signaling positive, as part of a rapid diagnostic testing protocol integrated with active antimicrobial stewardship program (ASP) support. 1

Optimal Implementation Strategy

Timing of Testing

  • Run BCID2 as soon as the blood culture bottle flags positive - this is when the test provides maximum clinical benefit by accelerating time to targeted therapy 2, 3
  • The test delivers results in <2 hours from positive bottle, compared to 24-48 hours for conventional identification and susceptibility testing 1
  • Studies show median time to targeted therapy improves from 24.2 hours (conventional) to 17.0 hours (with BCID2), representing approximately 1 day, 5 hours, and 35 minutes faster results 2, 4

Critical Success Factors

Active ASP integration is non-negotiable for clinical benefit. The 2025 ASM guidelines emphasize that rapid results become meaningless without timely communication to providers 1. Implementation requires:

  • Real-time communication protocols: Phone calls, text pages, or digital alerts to providers when actionable results are available 1
  • ASP team review and recommendations based on BCID2 results, with antimicrobial modifications occurring in approximately 28.8% of cases 2
  • 24/7 availability maximizes impact: Studies show mortality reduction only during hours when testing was available (weekday daytime), with no benefit in overall populations when testing was limited 3

When NOT to Run BCID2

Do not test bottles with likely contaminants - this wastes approximately 19.5% of reagent costs on negative results 5. Pre-analytical stewardship should:

  • Minimize skin contaminant testing through proper blood culture collection technique 1
  • Consider clinical context before reflexively testing every positive bottle
  • Establish protocols for when repeat testing is indicated 1

Important Caveats and Pitfalls

Off-Panel Pathogens

12-19.5% of positive blood cultures contain organisms not on the BCID2 panel 2, 5. A negative BCID2 result requires nuanced interpretation:

  • Does NOT rule out bloodstream infection
  • Conventional culture identification remains essential
  • Clinical decisions must incorporate the patient's overall context 2

Polymicrobial Infections

Concordance drops to 77.5-79% in polymicrobial samples 5, 6. Key challenges:

  • Resistance genes cannot be definitively attributed to a specific co-detected organism 5
  • May require multicolony subculture for accurate identification 7
  • ΔCp analysis (difference in crossing point values) can help identify discrepancies, particularly with CoNS 7

False Positives

Candida species show substantial false-positive rates, particularly C. tropicalis (often detected alongside C. parapsilosis) 8. This stems from:

  • Non-viable DNA fragments in blood culture media
  • Cross-reactivity in sensitive PCR analysis
  • Requires microbiological expertise for interpretation 8

Resistance Gene Detection

While resistance genes are detected in 93.4% of matched specimens 6, the qualitative-only output limits clinical utility:

  • Cannot quantify organism burden
  • In polymicrobial samples, cannot definitively link resistance gene to specific pathogen 5
  • mecA/C, CTX-M, and KPC are most frequently detected 5

Cost-Effectiveness Considerations

At approximately €250 per test 5, diagnostic stewardship is essential:

  • Target testing to patients with sepsis/septic shock where rapid de-escalation or escalation is critical 4
  • Avoid reflexive testing of all positive bottles
  • Monitor post-analytical actionability - results without action represent wasted costs 1

The mortality benefit (adjusted OR 0.50-0.58) is only realized when testing is continuously available and integrated with active ASP support 2, 3. Without these elements, BCID2 implementation shows no clinical benefit despite the expense.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.